doi: 10.1007/s00425-011-1349-4 23 GhantaS.ChattopadhyayS
Tirzepatide (Mounjaro for type 2 diabetes, Zepbound for weight management) is an FDA-approved dual GIP/GLP-1 receptor agonist that significantly slows gastric emptying
For patients who thrive on accountability and peer support, this community aspect can meaningfully impact adherence and long-term success
Patients taking insulin or sulfonylureas should contact their provider about possible dose adjustments if food intake decreases significantly, to prevent hypoglycemia
GLP-1 medications reduce appetite by slowing gastric emptying and signaling satiety centers in the hypothalamus, while lipotropic compounds support hepatic lipid metabolism by providing methyl donors for phosphatidylcholine synthesis
Dysregulation across any of these interconnected epigenetic layers, from DNA methylation through histone marks to chromatin architecture and non-coding RNA networks, serves as biomarkers for oocyte developmental competence, highlighting the value of multi-level epigenetic assessment over single-mark analysis [181,182,183,184] Table 2